DIBINEM, University of Bologna, Bologna, Italy.
Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4720-4725.
Supplementation with Mirtogenol® improves the retinal microcirculation and reduces intraocular pressure (IOP) in ocular hypertension, when administrated either alone or in association with an ophthalmic solution (latanoprost). In this study, microcirculatory parameters (perfusion of the circle of Zinn-Haller and retinal circulation) and oxidative stress were tested to assess the effects of Mirtogenol® plus traditional antihypertensive drugs in patients with elevated IOP.
88 otherwise healthy patients with increased IOP were followed-up in a supplement registry for 12 weeks. Three groups received; (a) dorzolamide-timolol plus Mirtogenol®; (b) latanoprost drops plus Mirtogenol® or (c) latanoprost only. Oral supplementation consisted of two tablets/day of Mirtogenol® (80 mg of bilberry extract, Mirtoselect® plus 40 mg of Pycnogenol®). IOP, retinal blood flow, perfusion of the circle of Zinn-Haller, and oxidative stress were measured during the registry period.
The three study groups were comparable; IOP and ocular blood flow velocity at inclusion were also comparable. Over the study period the decrease in IOP and the improvements in retinal microcirculation were statistically significant for all management groups, with a marginally more evident benefit in Mirtogenol®+latanosprost-treated patients. At 12 weeks, the altered perfusion at the circle of Zinn-Haller was improved in all groups; patients using Mirtogenol® showed a better perfusional pattern compared with subjects using only latanoprost. A reduction in oxidative stress was observed in supplemented subjects at the end of the study period; no significant change was seen in non-supplemented patients. All managements were well-tolerated without side effects.
Supplementation with Mirtogenol®, in addition to local ophthalmic treatments, is safe and may contribute as a supplementary management to reach a normal IOP and ocular microcirculatory parameters.
当米托君（Mirtogenol®）单独或与眼科溶液（拉坦前列素）联合用于治疗眼压升高时，可改善眼高血压患者的视网膜微循环并降低眼压（IOP）。在这项研究中，测试了微循环参数（Haller 环灌注和视网膜循环）和氧化应激，以评估米托君（Mirtogenol®）加传统降压药对眼压升高患者的影响。
88 名其他健康的眼压升高患者在补充登记处随访 12 周。三组患者分别接受以下治疗：（a）多佐胺-噻吗洛尔加米托君（Mirtogenol®）；（b）拉坦前列素滴眼液加米托君（Mirtogenol®）或（c）仅用拉坦前列素。口服补充剂包括每天两片米托君（Mirtogenol®）（80 毫克越桔提取物，Mirtoselect®加 40 毫克碧萝芷®）。在登记期间测量眼压、视网膜血流、Haller 环灌注和氧化应激。
三组研究对象具有可比性；纳入时的眼压和眼血流速度也具有可比性。在研究期间，所有治疗组的眼压下降和视网膜微循环改善均具有统计学意义，米托君（Mirtogenol®）+拉坦前列素治疗组的获益更为明显。在 12 周时，所有组的Haller 环灌注改变均得到改善；与仅使用拉坦前列素的患者相比，使用米托君（Mirtogenol®）的患者显示出更好的灌注模式。在研究结束时，补充组的氧化应激减少；未接受补充治疗的患者无明显变化。所有治疗方法均耐受良好，无副作用。
米托君（Mirtogenol®）补充治疗，除了局部眼科治疗外，是安全的，可能有助于达到正常的眼压和眼部微循环参数。
